Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSmith & Nephew Regulatory News (SN.)

Share Price Information for Smith & Nephew (SN.)

Share Price is delayed by 15 minutes
Get Live Data
1,147.50    8.50 (0.75%)
Bid:
1,147.00
Ask:
1,147.50
Spread: 0.50 (0.044%)
Market Cap: £9.74b
SN. Live PriceLast checked at - London Stock Exchange

Intraday Smith & Nephew Share Chart

Pre Stabilisation Notice

27 May 2026 09:31

RNS Number : 8736F
HSBC Bank plc
27 May 2026
Β 

27th May 2026

Β 

Smith & Nephew plc

Pre Stabilisation Notice

HSBC (contact: syndexecution@noexternalmail.hsbc.com) hereby gives notice, as Stabilisation Coordinator, that the Stabilisation Manager(s) named below may stabilise the offer of the following securities

The securities:

Issuer:

Smith & Nephew plc

Guarantor (if any):

n/a

Aggregate nominal amount:

EUR Benchmark

Description:

Fixed rate 12yr due 3rd Jun 2038

Offer price:

TBC

Other offer terms:

Stabilisation:

Stabilising Manager(s):

HSBC Bank plc

Stabilisation period expected to start on:

27th May 2026

Stabilisation period expected to end no later than:

3rd July 2026

Existence, maximum size & conditions of use of over-allotment facility[1]:

5% of the aggregate nominal amount

Stabilisation Venue(s)

Over the counter (OTC)

Β 

In connection with the offer of the above securities, the Stabilisation Manager(s) may over-allot the securities or effect transactions with a view to supporting the market price of the securities at a level higher than that which might otherwise prevail. However, there is no assurance that the Stabilisation Manager(s) will take any stabilisation action and any stabilisation action, if begun, may be ended at any time. Any stabilisation action or over-allotment shall be conducted in accordance with all applicable laws and rules.

This announcement is for information purposes only and does not constitute an invitation or offer to underwrite, subscribe for or otherwise acquire or dispose of any securities of the Issuer in any jurisdiction.

Β 

In addition, if and to the extent that this announcement is communicated in, or the offer of the securities to which it relates is made in, any EEA Member State before the publication of a prospectus in relation to the securities which has been approved by the competent authority in that Member State in accordance with the Regulation (EU) 2017/1129 (the "Prospectus Regulation") (or which has been approved by a competent authority in another Member State and notified to the competent authority in that Member State in accordance with the Prospectus Regulation), this announcement and the offer are only addressed to and directed at persons in that Member State who are qualified investors within the meaning of the Prospectus Regulation (or who are other persons to whom the offer may lawfully be addressed) and must not be acted on or relied on by other persons in that Member State.

Β 

This announcement and the offer of the securities to which it relates are only addressed to and directed at persons outside the United Kingdom and persons in the United Kingdom who have professional experience in matters related to investments or who are high net worth persons within article 12(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 and must not be acted on or relied on by other persons in the United Kingdom.

Β 

This announcement is not an offer of securities for sale into the United States. The securities have not been, and will not be, registered under the United States Securities Act of 1933 and may not be offered or sold in the United States absent registration or an exemption from registration. There will be no public offer of securities in the United States.


[1] Please note that the existence and the maximum size of any greenshoe option, the exercise period of the greenshoe option and any conditions for exercise of the greenshoe option must also be disclosed, if such option exists. In addition, the exercise of the greenshoe option must be disclosed to the public promptly, together with all appropriate details, including in particular the date of exercise and the number and nature of securities involvedΒ 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
STAZZGZKRNRGVZG
Date   Source Headline
5th Jun 202612:12 pmRNSTransaction in Own Shares
4th Jun 20264:05 pmRNSDirector/PDMR Shareholding
3rd Jun 202611:21 amRNSDirector/PDMR Shareholding
3rd Jun 202610:35 amRNSAdmission to Trading
1st Jun 20263:10 pmRNSTotal Voting Rights
29th May 202610:37 amRNSTransaction in Own Shares
27th May 20269:31 amRNSPre Stabilisation Notice
22nd May 20261:32 pmRNSAdmission to Trading
22nd May 20269:58 amRNSTransaction in Own Shares
20th May 202611:25 amRNSDirector/PDMR Shareholding
19th May 20268:53 amRNSHolding(s) in Company
15th May 202612:28 pmRNSTransaction in Own Shares Replacement
15th May 202611:41 amRNSTransaction in Own Shares
14th May 20269:25 amRNSHolding(s) in Company
12th May 20264:03 pmRNSSterling Amount of Dividend
8th May 20267:00 amRNSShare Buyback Programme
6th May 20262:25 pmRNSResult of AGM
6th May 20267:00 amRNSSmith+Nephew First Quarter 2026 Trading Update
1st May 20261:10 pmRNSTotal Voting Rights
27th Apr 20267:00 amRNSExpert surgeons insights event for investors
22nd Apr 20268:46 amRNSNotice of Results
16th Apr 202611:12 amRNSDirector/PDMR Shareholding
15th Apr 20263:46 pmRNSDirector Declaration
14th Apr 20262:59 pmRNSReplacement: Annual Financial Report & AGM Notice
1st Apr 202612:23 pmRNSTotal Voting Rights
24th Mar 20264:16 pmRNSDirector/PDMR Shareholding
24th Mar 20268:45 amRNSHolding(s) in Company
16th Mar 20263:08 pmRNSAnnual Financial Report & Notice of AGM
16th Mar 20263:08 pmRNSAnnual Financial Report & Notice of AGM
10th Mar 20262:30 pmRNS-RSmith+Nephew launches next-generation ALLEVYN™ COMPLETE CARE Foam Dressing - designed for high performance in wound management and pressure injury prevention
5th Mar 20267:30 amRNSDirector Declaration
2nd Mar 20261:36 pmRNSTotal Voting Rights
2nd Mar 20267:00 amRNSFinal Results
5th Feb 202611:56 amRNSNotice of Results
2nd Feb 20264:00 pmRNSBLOCK LISTING SIX MONTHLY RETURN
2nd Feb 20263:05 pmRNSTotal Voting Rights
23rd Jan 20262:00 pmRNSDirector/PDMR Shareholding
21st Jan 20264:11 pmRNSCompletion of Acquisition
12th Jan 20264:30 pmRNSAcquisition of Integrity Orthopaedics
2nd Jan 202610:07 amRNSTotal Voting Rights
8th Dec 20257:00 amRNSNew Strategy and 2028 Financial Targets
1st Dec 20254:10 pmRNSTotal Voting Rights
19th Nov 202510:00 amRNSDirector/PDMR Shareholding
18th Nov 202510:18 amRNSHolding(s) in Company
12th Nov 20259:24 amRNSDirector/PDMR Shareholding
11th Nov 20254:40 pmRNSHolding(s) in Company
10th Nov 20251:46 pmRNSDirector/PDMR Shareholding
7th Nov 20259:38 amRNSDirector/PDMR Shareholding
7th Nov 20259:35 amRNSDirector/PDMR Shareholding
6th Nov 20257:01 amRNSDirectorate change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.